» Articles » PMID: 36358843

Protein Kinase C (PKC) Isozymes As Diagnostic and Prognostic Biomarkers and Therapeutic Targets for Cancer

Overview
Journal Cancers (Basel)
Publisher MDPI
Specialty Oncology
Date 2022 Nov 11
PMID 36358843
Authors
Affiliations
Soon will be listed here.
Abstract

Protein kinase C (PKC) is a large family of calcium- and phospholipid-dependent serine/threonine kinases that consists of at least 11 isozymes. Based on their structural characteristics and mode of activation, the PKC family is classified into three subfamilies: conventional or classic (cPKCs; α, βI, βII, and γ), novel or non-classic (nPKCs; δ, ε, η, and θ), and atypical (aPKCs; ζ, ι, and λ) (PKCλ is the mouse homolog of PKCι) PKC isozymes. PKC isozymes play important roles in proliferation, differentiation, survival, migration, invasion, apoptosis, and anticancer drug resistance in cancer cells. Several studies have shown a positive relationship between PKC isozymes and poor disease-free survival, poor survival following anticancer drug treatment, and increased recurrence. Furthermore, a higher level of PKC activation has been reported in cancer tissues compared to that in normal tissues. These data suggest that PKC isozymes represent potential diagnostic and prognostic biomarkers and therapeutic targets for cancer. This review summarizes the current knowledge and discusses the potential of PKC isozymes as biomarkers in the diagnosis, prognosis, and treatment of cancers.

Citing Articles

Imaging the Raf-MEK-ERK Signaling Cascade in Living Cells.

Shin Y, Cho M, Hwang J, Myung K, Kweon H, Lee Z Int J Mol Sci. 2024; 25(19).

PMID: 39408915 PMC: 11477372. DOI: 10.3390/ijms251910587.


An Ingenane-Type Diterpene from Promoted Cell Apoptosis and Macrophage Polarization via the Regulation of PKC Signaling Pathways.

Feng X, Wang L, Pu L, Li J, Li H, Liu D Int J Mol Sci. 2024; 25(18).

PMID: 39337608 PMC: 11432454. DOI: 10.3390/ijms251810123.


Prenatal opioid exposure significantly impacts placental protein kinase C (PKC) and drug transporters, leading to drug resistance and neonatal opioid withdrawal syndrome.

Radhakrishna U, Radhakrishnan R, Uppala L, Muvvala S, Prajapati J, Rawal R Front Neurosci. 2024; 18:1442915.

PMID: 39238930 PMC: 11376091. DOI: 10.3389/fnins.2024.1442915.


Glutathione-Dependent Pathways in Cancer Cells.

Kalinina E Int J Mol Sci. 2024; 25(15).

PMID: 39125992 PMC: 11312684. DOI: 10.3390/ijms25158423.


Anti-Neuroinflammatory Effects of a Macrocyclic Peptide-Peptoid Hybrid in Lipopolysaccharide-Stimulated BV2 Microglial Cells.

Sun L, Saliba S, Apweiler M, Akmermer K, Herlan C, Grathwol C Int J Mol Sci. 2024; 25(8).

PMID: 38674048 PMC: 11049839. DOI: 10.3390/ijms25084462.


References
1.
Tang C, Wang Y, Zhang L, Wang J, Wang W, Han X . Identification of novel LncRNA targeting Smad2/PKCα signal pathway to negatively regulate malignant progression of glioblastoma. J Cell Physiol. 2019; 235(4):3835-3848. PMC: 6972644. DOI: 10.1002/jcp.29278. View

2.
Sharif T, Sharif M . Overexpression of protein kinase C epsilon in astroglial brain tumor derived cell lines and primary tumor samples. Int J Oncol. 1999; 15(2):237-43. View

3.
Newton A . Protein kinase C: perfectly balanced. Crit Rev Biochem Mol Biol. 2018; 53(2):208-230. PMC: 5901981. DOI: 10.1080/10409238.2018.1442408. View

4.
Piperno-Neumann S, Larkin J, Carvajal R, Luke J, Schwartz G, Hodi F . Genomic Profiling of Metastatic Uveal Melanoma and Clinical Results of a Phase I Study of the Protein Kinase C Inhibitor AEB071. Mol Cancer Ther. 2020; 19(4):1031-1039. DOI: 10.1158/1535-7163.MCT-19-0098. View

5.
zum Buschenfelde C, Wagner M, Lutzny G, Oelsner M, Feuerstacke Y, Decker T . Recruitment of PKC-betaII to lipid rafts mediates apoptosis-resistance in chronic lymphocytic leukemia expressing ZAP-70. Leukemia. 2009; 24(1):141-52. DOI: 10.1038/leu.2009.216. View